ARWR at a glance
ARROWHEAD PHARMACEUTICALS, INC. (ARWR, SEC CIK 879407) filed its latest 10-K annual report on November 12, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as August 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended September 30, 2026 (FY2026), ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported revenue of $450.8 million (down 45.6% from FY2025) and a net loss of $724.2 million. Diluted EPS was -$5.11.
- As of September 30, 2026, 33 institutional investment managers tracked by SignalX reported holding ARROWHEAD PHARMACEUTICALS, INC. (ARWR) shares worth $3.3 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by OLUKOTUN ADEOYE Y on August 18, 2026 of 2,000 shares at $86.96 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $450.8M
- −45.6% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 33 funds
- $3.3B · −2 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $450.8M, down $378.6M YoY from $829.4M, driven by lower Sarepta and Sanofi collaboration revenue
- Net loss $724.2M vs $1.6M; operating loss $707.2M vs operating income $98.3M
- Best performer: Sarepta revenue $316.9M; worst: Sanofi revenue $13.3M, down from $130.0M
- Operating cash flow $(271.9)M; capex $12.0M; PRV purchase $215.0M; convertible-note proceeds $681.3M
- Outlook: liquidity sufficient for at least 12 months; planned U.S. sHTG launch in Q2 2027 pending approval
Risk Factors
- FDA approval risk: plozasiran sNDA for sHTG remains pending despite STAR pilot entry
- Pricing pressure: CMS GLOBE Medicare Part B model begins in 2027 and faces pending litigation
- Supply-chain exposure: reliance on third parties in China creates BIOSECURE Act and tariff disruption risk
- Competitive disruption: generic REDEMPLO versions could erode sales if exclusivity is inadequate
- Leverage constraint: Sixth Street financing agreement could accelerate debt repayment upon covenant breach
Business Overview
- RNAi biopharmaceutical model: proprietary TRiM platform develops gene-silencing medicines, with partnered programs funding wholly owned assets
- First commercial product REDEMPLO launched in 2025, with approvals expanded to the EU, Canada, Australia, China and UK
- Strategic shift toward commercialization: commercial organization built for FCS and larger footprint planned for potential sHTG launch in Q2 2027
- Plozasiran Phase 3 results: median triglyceride reductions of 79% and 81% at Month 12, with STAR pilot acceptance for the sNDA
- Workforce expanded to 1,062 employees across the United States, Switzerland and New Zealand, supporting commercialization, manufacturing and R&D growth
AI summary of the ARWR 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Outlook centered on plozasiran development, regulatory approval, commercialization, and potential future revenues
- Headwinds include clinical, regulatory, partnership, milestone, royalty, liquidity, and capital requirement uncertainties
Risk Factors
- No material changes to risk factors identified in the September 30, 2025 Form 10-K
- Carried-forward risks include business, operating-results, and financial-condition uncertainty
- No newly added regulatory, legal, compliance, operational, competitive, market, liquidity, debt, currency, or concentration risk disclosed
AI summary of the ARWR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Fiscal 2026 results cover the period ended September 30, 2026
- Press release announces and discusses Arrowhead’s full-year financial results
Item EX-99.1: Item EX-99.1
- FY2026 revenue $450.8M, down from $829.4M, while net loss widened to $724.2M from $1.6M
- REDEMPLO adoption accelerating: prescriptions up 63% quarter over quarter, 950 cumulative U.S. prescriptions, 160M covered lives
Item 1.01: Entry into a Material Definitive Agreement
- $400.0M senior secured facility fully funded November 2, 2026, maturing November 2, 2031
- Interest reduced from 15.0% paid-in-kind to Term SOFR plus 5.50% or base rate plus 4.50%, payable quarterly in cash
Item 2.03: Creation of a Direct Financial Obligation
- Item 2.03 links financial obligations to Item 1.01, indicating a material agreement created direct debt or payment obligations
- Investors must review the incorporated Item 1.01 terms to assess amount, interest, maturity and use of proceeds
Item EX-99.1: Item EX-99.1
- $400 million refinancing replaces 15% debt with SOFR plus 5.50%, materially reducing borrowing costs
- Existing facility retired at a $68 million discount to its contractual minimum repayment amount
Item 2.02: Results of Operations and Financial Condition
- Fiscal 2026 results covered year ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing management’s financial commentary
Item EX-99.1: Item EX-99.1
- Fiscal Q3 revenue $75.3M vs $27.8M, while net loss attributable to Arrowhead widened to $194.3M from $175.2M
- REDEMPLO prescription volume roughly doubled, with more than 400 prescribing practitioners and improving major-payer coverage
AI summaries of ARWR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ARWR
Don't miss the next ARWR filing
- Alerts as it files. A push when ARWR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ARWR, by share count.
- Ask anything. An AI agent that reads every ARWR filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| OLUKOTUN ADEOYE Y | Sell | Aug 18, 2026 | 2,000 | $86.96 |
| PERRY MICHAEL S | Sell | Aug 18, 2026 | 11,600 | $87.30 |
| Cohen Matthew Gregory | A | Jun 15, 2026 | 11,882 | - |
| Lu Hongbo | Sell | May 12, 2026 | 2,970 | $76.88 |
| Lu Hongbo | Sell | May 12, 2026 | 2,970 | $76.88 |
| Hamilton James C | Sell | Apr 23, 2026 | 10,000 | $75.00 |
| Apel Daniel Joseph | Sell | Apr 22, 2026 | 1,157 | $70.45 |
| Apel Daniel Joseph | Sell | Apr 22, 2026 | 3,208 | $70.11 |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $829.4M | $450.8M |
| Operating Income | -$601.1M | $98.3M | -$707.2M |
| Net Income | -$599.5M | -$1.6M | -$724.2M |
| Op. Margin | - | 11.9% | -156.9% |
| Net Margin | - | -0.2% | -160.6% |
| Balance Sheet | |||
| Total Assets | - | $1.4B | $1.7B |
| Equity | - | $466.1M | $50.3M |
| ROE | - | -0.3% | -1439.4% |
| Per Share | |||
| EPS | - | $-0.01 | $-5.11 |
| Cash Flow | |||
| Operating CF | -$462.9M | $179.6M | -$271.9M |
| CapEx | $141.5M | $22.7M | $12.0M |
Source: XBRL data in ARROWHEAD PHARMACEUTICALS, INC. (ARWR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ARWR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 33 | $3.25B |
| Q2 2026 | 35 | $4.64B |
| Q1 2026 | 36 | $3.86B |
| Q4 2025 | 31 | $4.02B |
| Q3 2025 | 29 | $2.08B |
| Q2 2025 | 30 | $908.0M |
| Q1 2025 | 26 | $446.3M |
| Q4 2024 | 21 | $549.3M |
- Morgan Stanley+750.3K (+69%)
- Two Sigma Investments+502.8K (+87%)
- State Street Corp+427.6K (+8%)
- BlackRock+310.3K (+2%)
- Ameriprise Financial+187.6K (+120%)
- Renaissance Technologies LLC−434.9K (-93%)
- Goldman Sachs Group−301.0K (-26%)
- D.E. Shaw & Co−272.8K (-63%)
- Bank of America Corp−198.2K (-17%)
- Principal Financial Group−147.3K (-29%)
- Citadel Advisors LLC+197.7K
- FMR LLC (Fidelity)−8.04M
- Blackstone Group−5.2K
- Citizens Financial Group−3.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 241 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ARWR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 10-K | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 4 | Jun 17, 2026 | - | - | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
| 4 | May 14, 2026 | - | - | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | May 6, 2026 | - | - | |
| SC 13G | Apr 29, 2026 | - | - | |
| SC 13G | Apr 28, 2026 | - | - | |
| 4 | Apr 24, 2026 | - | - | - |
| 4 | Apr 24, 2026 | - | - | - |
| 8-K | Mar 20, 2026 | - | - | - |
| 4 | Mar 9, 2026 | - | - | - |
| 10-Q | Feb 5, 2026 | Dec 31, 2025 | Analysis | |
| 8-K | Feb 5, 2026 | - | - | |
| 8-K | Jan 12, 2026 | - | - | |
| 8-K | Jan 9, 2026 | - | - | |
| 4 | Jan 8, 2026 | - | - | |
| 4 | Jan 8, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ARWR SEC filings: frequently asked questions
Which institutions hold ARWR stock?
As of September 30, 2026, the largest ARROWHEAD PHARMACEUTICALS, INC. (ARWR) holders among the 13F filers tracked by SignalX were BlackRock ($991.0 million), Vanguard Portfolio Management LLC ($406.5 million), State Street Corp ($400.7 million), Vanguard Capital Management LLC ($400.5 million), Invesco Ltd ($250.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ARWR's revenue in fiscal year 2026?
For the fiscal year ended September 30, 2026 (FY2026), ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported revenue of $450.8 million (down 45.6% from FY2025) and a net loss of $724.2 million. Diluted EPS was -$5.11. The figures come from the XBRL data in the 10-K.
What are the main risks in ARWR's latest 10-K?
In the 10-K filed November 12, 2026, ARROWHEAD PHARMACEUTICALS, INC. (ARWR) flagged: FDA approval risk: plozasiran sNDA for sHTG remains pending despite STAR pilot entry. Pricing pressure: CMS GLOBE Medicare Part B model begins in 2027 and faces pending litigation. (AI summary of the Risk Factors section.)
What did ARWR report in its latest 8-K?
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Fiscal 2026 results cover the period ended September 30, 2026.
What are the latest ARWR SEC filings?
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) filed its latest 10-K annual report on November 12, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on August 20, 2026.
What is ARWR's SEC CIK number?
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)'s SEC Central Index Key (CIK) is 879407. EDGAR lists every ARWR filing under that number.
Ask anything about ARWR
The research agent reads ARWR's filings, financials, insider trades and 13F holders, then answers with sources.